SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:0959 8138 OR L773:1756 1833
 

Sökning: L773:0959 8138 OR L773:1756 1833 > Montelukast and flu...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004354naa a2200469 4500
001oai:lup.lub.lu.se:b6ddf8db-a6f6-4f1a-815f-207470930d96
003SwePub
008160401s2003 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/2984712 URI
0247 a https://doi.org/10.1136/bmj.327.7420.8912 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Bjermer, Leifu Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)lung-lbj
2451 0a Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial
264 1b BMJ,c 2003
338 a electronic2 rdacarrier
520 a Objectives To assess the effect of montelukast versus salmeterol added to inhaled fluticasone propionate on asthma exacerbation in patients whose symptoms are inadequately controlled with fluticasone alone. Design and setting A 52 week, two period, double blind, multicentre trial during which patients whose symptoms remained uncontrolled by inhaled corticosteroids were randomised to add montelukast or salmeterol. Participants Patients (15-72 years; n = 1490) had a clinical history of chronic asthma for greater than or equal to1 year, a baseline forced expiratory volume in one second (FEV1) value 50-90% predicted, and a beta agonist improvement of greater than or equal to 12% in FEV1. Main outcome measures The primary end point was the percentage of patients with at least one asthma exacerbation. Results 20.1% of the patients in the group receiving montelukast and fluticasone had an asthma exacerbation compared with 19.1% in the group receiving salmeterol and fluticasone; the difference was 1% (95% confidence interval - 3.1% to 5.0%). With a risk ratio (montelukast-fluticasone/ salmeterol-fluticasone) of 1.05 (0.86 to 1.29), treatment with montelukast and fluticasone was shown to be non-inferior to treatment with salmeterol and fluticasone. Salmeterol and fluticasonc significantly increased FEV1 before a beta agonist was used and morning peak expiratory flow compared with montelukast and fluticasone (P less than or equal to0.001), whereas FEV1 after a beta agonist was used and improvements in asthma specific quality of life and nocturnal awakenings were similar between the groups. Montelukast and fluticasone significantly (P = 0.011) reduced peripheral blood eosinophil counts compared with salmeterol and fluticasone. Both treatments were generally well tolerated. Conclusion The addition of montelukast in patients whose symptoms remain uncontrolled by inhaled fluticasone could provide equivalent clinical control to salmeterol.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Lungmedicin och allergi0 (SwePub)302192 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Respiratory Medicine and Allergy0 (SwePub)302192 hsv//eng
7001 a Bisgaard, H4 aut
7001 a Bousquet, J4 aut
7001 a Fabbri, LM4 aut
7001 a Greening, AP4 aut
7001 a Haahtela, T4 aut
7001 a Holgate, ST4 aut
7001 a Picado, C4 aut
7001 a Menten, J4 aut
7001 a Dass, SB4 aut
7001 a Leff, JA4 aut
7001 a Polos, PG4 aut
7102 a Lungmedicin, allergologi och palliativ medicinb Sektion II4 org
7730 t BMJ: British Medical Journald : BMJg 327:7420, s. 891-895q 327:7420<891-895x 1756-1833
7730 t BMJd : BMJg 327:7420, s. 891-895q 327:7420<891-895x 0959-8138x 1468-5833
8564 u https://portal.research.lu.se/files/2808626/623879.pdfx primaryx freey FULLTEXT
8564 u http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=14563743&dopt=Abstractx freey FULLTEXT
8564 u http://dx.doi.org/10.1136/bmj.327.7420.891x freey FULLTEXT
8564 u https://www.bmj.com/content/327/7420/891.full.pdf
8564 8u https://lup.lub.lu.se/record/298471
8564 8u https://doi.org/10.1136/bmj.327.7420.891

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy